Cediranib Versus Placebo Plus Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers

ABSTRACT: As a result of our previous NCRN study (ABC-02) cisplatin and gemcitabine (CisGem) is likely to become the international standard of care for patients with advanced biliary tract cancer (submitted: ASCO 2009). This study, ABC-03, will determine whether the addition of cediranib(an oral Vascular Endothelial Growth Factor Receptor inhibitor) to CisGem will improve the time to disease progression in this patient group.

DISEASE(S): Biliary Tract Neoplasms,Biliary Tract Carcinomas (including Gallbladder Cancer And Cholangiocarcinomas),Upper Gastro-intestinal Cancer,Cholangiocarcinoma Non-resectable,Gallbladder Cancer Non-resectable,Biliary Tract,Bile Duct Cancer Nos

PROVIDER: 2075190 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR